VKTX Price Action: According to data from Benzinga Pro, Viking Therapeutics stock was down 1.12% after hours at $25.50 on Wednesday.

Viking's Phase 1 study for the oral formulation was a randomized, double-blind, placebo controlled study in healthy adults with a minimum body mass index of 30 kilograms per meter squared.

Research and Development Expenses: $41.4 million for Q1 2025, up from $24.1 million in Q1 2024 ... down from $903 million as of December 31, 2024. Viking Therapeutics Inc (NASDAQ:VKTX) announced ...

SAN DIEGO - Viking Therapeutics, Inc. (NASDAQ:VKTX) reported a wider-than-expected loss for the first quarter of 2025 as research and development expenses increased, but its stock edged up 1% ...

Our proven model does not predict an earnings beat for Viking this time around. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds ...

Cardiff-based Nigerian born designer Temitope Ogunseitan showcased his A/W 25 collection “Biophilic” during London Fashion Week and I was thrilled to be invited to view this latest body of work.

Viking® (www.viking.com) has announced its newest ship for the Nile River—the 82-guest Viking Amun—was “floated out,” marking a major construction milestone and the first time the ship ...

Following the earnings announcement, Viking Therapeutics’ stock fell 1.71% in after-hours trading, closing at $25.35. The stock has seen significant volatility, trading 68% below its 52-week high of ...

There is currently no schedule data. The NFL Schedule will be released in May.